Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants.

Show simple item record

dc.contributor.author Ozben, Tomris
dc.contributor.author Saso, Luciano
dc.contributor.author De Luca, Chiara
dc.contributor.author Korkina, Liudmila
dc.contributor.author Cort, Aysegul
dc.date.accessioned 2021-06-24T07:48:56Z
dc.date.available 2021-06-24T07:48:56Z
dc.date.issued 2016
dc.identifier.issn 1942-0900
dc.identifier.other 26881027
dc.identifier.uri https://doi.org/ 10.1155/2016/4251912 en_US
dc.identifier.uri http://openaccess.sanko.edu.tr/xmlui/handle/20.500.12527/255
dc.description.abstract Clinical efficacy of anticancer chemotherapies is dramatically hampered by multidrug resistance (MDR) dependent on inherited traits, acquired defence against toxins, and adaptive mechanisms mounting in tumours. There is overwhelming evidence that molecular events leading to MDR are regulated by redox mechanisms. For example, chemotherapeutics which overrun the first obstacle of redox-regulated cellular uptake channels (MDR1, MDR2, and MDR3) induce a concerted action of phase I/II metabolic enzymes with a temporal redox-regulated axis. This results in rapid metabolic transformation and elimination of a toxin. This metabolic axis is tightly interconnected with the inducible Nrf2-linked pathway, a key switch-on mechanism for upregulation of endogenous antioxidant enzymes and detoxifying systems. As a result, chemotherapeutics and cytotoxic by-products of their metabolism (ROS, hydroperoxides, and aldehydes) are inactivated and MDR occurs. On the other hand, tumour cells are capable of mounting an adaptive antioxidant response against ROS produced by chemotherapeutics and host immune cells. The multiple redox-dependent mechanisms involved in MDR prompted suggesting redox-active drugs (antioxidants and prooxidants) or inhibitors of inducible antioxidant defence as a novel approach to diminish MDR. Pitfalls and progress in this direction are discussed. en_US
dc.language.iso English en_US
dc.publisher HINDAWI LTD, ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject ARYL-HYDROCARBON RECEPTOR en_US
dc.subject NF-KAPPA-B en_US
dc.subject NATURAL-PRODUCT MODULATORS en_US
dc.subject PROMOTES TUMOR-GROWTH en_US
dc.subject LUNG-CANCER CELLS en_US
dc.subject OXIDATIVE STRESS en_US
dc.subject HUMAN KERATINOCYTES en_US
dc.subject PLANT POLYPHENOLS en_US
dc.subject THIOREDOXIN-1 INHIBITOR en_US
dc.subject CHEMOTHERAPEUTIC-AGENTS en_US
dc.title Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants. en_US
dc.type Other en_US
dc.relation.journal OXIDATIVE MEDICINE AND CELLULAR LONGEVITY en_US
dc.contributor.authorID 0000-0002-1413-4523 : Tomris Ozben en_US
dc.contributor.authorID 0000-0003-4530-8706 : Luciano Saso en_US
dc.identifier.wos 000372420700001 en_US
dc.identifier.doi 10.1155/2016/4251912 en_US
dc.contributor.sankoauthor Ayşegül Çört en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Gazimuhtar Paşa Bulvarı
No:36
27090
Şehitkamil / GAZİANTEP